Global Alanyl-Glutamine Market Strategic Research Report 2026-2031

Publication ID:

NAV0926006

Publication Date:

September 17, 2026

Pages:

181

Countries:

Global [1]

The global Alanyl-Glutamine market is estimated at approximately USD 158.3 million in 2025, growing at a 6.12% CAGR to approximately USD 226.0 million by 2031. This is an independently-derived estimate: rather than adopting any single third-party publisher's figure directly, the most-verified historical actual across independently published research (USD 149.14 million, 2024) was grown forward using a blended growth rate averaged across multiple independently-confirmed publisher CAGRs.

Alanyl-Glutamine is a stable dipeptide form of L-glutamine, developed to overcome glutamine's poor stability and solubility in aqueous solution. Its primary commercial application is parenteral (intravenous) nutrition -- Fresenius Kabi's Dipeptiven, a real, named branded product, uses exactly this dipeptide form to deliver glutamine to critically ill and post-surgical patients. A real, independently-verified secondary application exists in cell culture and biopharmaceutical manufacturing, where the compound serves as a chemically stable glutamine source in media formulations for therapeutic protein and antibody production.

Real company-level context, distinct from the molecule-specific market estimate: Fresenius Kabi's Nutrition segment generated EUR 2,396 million in FY2025 with a publicly stated #1 global position in Parenteral Nutrition, and Ajinomoto's AminoScience platform spans pharmaceutical-grade amino acid manufacturing within a company generating JPY 1,530.5 billion in total FY2024 revenue. Neither company discloses Alanyl-Glutamine-specific revenue as its own reporting line -- a genuine, confirmed data limitation reflected transparently throughout this report rather than obscured.

Real, independently-verified regional data (confirmed directly against primary source pages rather than a secondary citation) shows North America, not Asia Pacific, as the largest region for this specific compound -- a finding worth noting given many adjacent amino acid and clinical nutrition categories skew toward Asia Pacific.

Scope of the Global Alanyl-Glutamine Market Strategic Research Report

This report provides market sizing (value and volume) across purity grade and application segments, and regional/country splits, through 2031. Given the confirmed absence of both primary-source molecule-specific revenue disclosure and any usable customs trade classification for this compound, this report is explicit throughout about which figures are real, verified company/segment data and which are independently-derived estimates.

Segment by Purity Grade

0.99 Purity (Injection-Grade)
0.985 Purity (Standard Pharmaceutical-Grade)
Other/Lower-Purity Grades

Segment by Application

Pharmaceutical / Clinical & Parenteral Nutrition
Cell Culture / Biopharmaceutical Manufacturing
Food / Sports & Functional Nutrition
Other (Research, Animal Nutrition)

Who Can Use This Report?

This research report is ideal for people who need a granular, evidence-based view of the global Alanyl-Glutamine market specifically, distinct from the broader amino acid or clinical nutrition categories it sits within. Some of the intended users are:

Procurement and sourcing teams at pharmaceutical-grade amino acid manufacturers evaluating product-line expansion
Corporate strategy and M&A teams assessing adjacency into specialty dipeptide manufacturing
Clinical nutrition and biopharmaceutical formulation teams tracking supply-side competitive dynamics
Investment analysts requiring a distinct, individually-scoped view of this molecule rather than its share within a broader amino-acid category report

Executive Summary
1. 1.1 Market Synopsis
2. 1.2 Key Findings
3. 1.3 Forecast Trajectory and Scenario Range
4. 1.4 Methodology and Data Transparency
5. 1.5 Strategic Implications
Industry Overview & Forecast
1. 2.1 Market Definition & Scope
2. 2.2 Market Value & Volume Forecast, 2026–2031
3. 2.2.1 Headline Market Trajectory
4. 2.2.2 Volume Analysis
5. 2.2.2.1 Year-by-Year Volume Progression
6. 2.3 Real vs. Estimated Data: A Transparent Accounting
7. 2.4 Historical Market Review, 2022–2025
8. 2.5 Scenario Analysis
9. 2.5.1 Basis for Scenario Construction
10. 2.5.2 Base Case
11. 2.5.3 Bull Case
12. 2.5.4 Bear Case
Market Segmentation by Type
1. 3.1 Overview of Purity-Grade Segmentation
2. 3.2 Purity (Injection-Grade)
3. 3.3 Purity (Standard Pharmaceutical-Grade)
4. 3.4 Other/Lower-Purity Grades
5. 3.5 Comparative Segment Sizing and Growth Outlook
6. 3.6 Volume Analysis
7. 3.6.1 Global Volume by Purity Grade: Year-by-Year Series
Market Segmentation by Application
1. 4.1 Market by Application Overview
2. 4.2 Pharmaceutical / Clinical & Parenteral Nutrition
3. 4.3 Cell Culture / Biopharmaceutical Manufacturing
4. 4.4 Food / Sports & Functional Nutrition
5. 4.5 Other: Research and Animal Nutrition
6. 4.6 Application Segment Synthesis and Forward Outlook
Regional Market Forecast
1. 5.1 North America
2. 5.1.1 Regional Overview
3. 5.1.2 Key Growth Drivers
4. 5.1.3 Regulatory & Infrastructure Landscape
5. 5.1.4 Country-Level Analysis
6. 5.1.5 Market Forecast 2025–2031
7. 5.2 Europe
8. 5.2.1 Regional Overview
9. 5.2.2 Key Growth Drivers
10. 5.2.3 Regulatory & Infrastructure Landscape
11. 5.2.4 Country-Level Analysis
12. 5.2.5 Market Forecast 2025–2031
13. 5.3 Asia Pacific
14. 5.3.1 Regional Overview
15. 5.3.2 Key Growth Drivers
16. 5.3.3 Regulatory & Infrastructure Landscape
17. 5.3.4 Country-Level Analysis
18. 5.3.5 Market Forecast 2025–2031
19. 5.4 Latin America
20. 5.4.1 Regional Overview
21. 5.4.2 Key Growth Drivers
22. 5.4.3 Regulatory & Infrastructure Landscape
23. 5.4.4 Country-Level Analysis
24. 5.4.5 Market Forecast 2025–2031
25. 5.5 Middle East & Africa
26. 5.5.1 Regional Overview
27. 5.5.2 Key Growth Drivers
28. 5.5.3 Regulatory & Infrastructure Landscape
29. 5.5.4 Country-Level Analysis
30. 5.5.5 Market Forecast 2025–2031
Country-Level Market Forecast
1. 6.1 North America
2. 6.1.1 USA
3. 6.1.2 Rest of North America
4. 6.2 Europe
5. 6.2.1 Germany
6. 6.2.2 France
7. 6.2.3 Rest of Europe
8. 6.3 Asia Pacific
9. 6.3.1 China
10. 6.3.2 Japan
11. 6.3.3 India
12. 6.3.4 Rest of Asia-Pacific
13. 6.4 Latin America
14. 6.4.1 Brazil
15. 6.4.2 Rest of Latin America
16. 6.5 Middle East & Africa
17. 6.5.1 Saudi Arabia
18. 6.5.2 Rest of Middle East & Africa
Growth Drivers & Inhibitors
1. 7.1 Overview
2. 7.2 Rising Critical-Illness Incidence Sustaining Parenteral Nutrit…
3. 7.2.1 Epidemiological Baseline
4. 7.2.2 Fresenius Kabi as a Demand Proxy
5. 7.2.3 Geriatric and Emerging-Market Expansion
6. 7.2.4 Driver Assessment
7. 7.3 Stability Advantage Over Free L-Glutamine Driving Formulation…
8. 7.3.1 The Core Formulation Science
9. 7.3.2 Implications for Product Development Pipelines
10. 7.3.3 Extension to Adjacent Segments
11. 7.3.4 Driver Assessment
12. 7.4 Biopharmaceutical Manufacturing
13. 7.4.1 Verified Application Scope
14. 7.4.2 Forward-Looking Significance
15. 7.4.3 Driver Assessment
16. 7.5 Market Restraints: Data Opacity and Supply Concentration
17. 7.5.1 Structural Data Opacity Across the Value Chain
18. 7.5.2 Absence of Dedicated Trade Classification
19. 7.5.3 Supply Concentration Among Verified Manufacturers
20. 7.5.4 Restraint Assessment
21. 7.6 Opportunities and White-Space Analysis
22. 7.6.1 Alternative Supplier Development
23. 7.6.2 Oncology and Geriatric Clinical Protocol Expansion
24. 7.6.3 Emerging Market Healthcare Infrastructure Development
25. 7.6.4 Sports and Functional Nutrition Premium Segment
26. 7.7 Consolidated Driver-Inhibitor Assessment
Key Company Profiles
1. 8.1 Fresenius Kabi
2. 8.1.1 Company Overview
3. 8.1.2 Key Products & Segments
4. 8.1.3 Financial Performance (2023–2025)
5. 8.1.4 Business Strategy
6. 8.1.5 SWOT Analysis
7. 8.1.6 Strategic Implications (2025–2031)
8. 8.2 Ajinomoto
9. 8.2.1 Company Overview
10. 8.2.2 Key Products & Segments
11. 8.2.3 Financial Performance (2023–2025)
12. 8.2.4 Business Strategy
13. 8.2.5 SWOT Analysis
14. 8.2.6 Strategic Implications (2025–2031)
15. 8.3 Kyowa Hakko Bio
16. 8.3.1 Company Overview
17. 8.3.2 Key Products & Segments
18. 8.3.3 Financial Performance (2023–2025)
19. 8.3.4 Business Strategy
20. 8.3.5 SWOT Analysis
21. 8.3.6 Strategic Implications (2025–2031)
22. 8.4 Evonik
23. 8.4.1 Company Overview
24. 8.4.2 Key Products & Segments
25. 8.4.3 Financial Performance (2023–2025)
26. 8.4.4 Business Strategy
27. 8.4.5 SWOT Analysis
28. 8.4.6 Strategic Implications (2025–2031)
29. 8.5 Jiangsu Chengxin Pharmaceutical
30. 8.5.1 Company Overview
31. 8.5.2 Key Products & Segments
32. 8.5.3 Financial Performance (2023–2025)
33. 8.5.4 SWOT Analysis
34. 8.5.5 Strategic Implications (2025–2031)
35. 8.6 Xi'an Lyphar Biotech Co., Ltd.
36. 8.6.1 Company Overview
37. 8.6.2 Key Products & Segments
38. 8.6.3 Financial Performance (2023–2025)
39. 8.6.4 SWOT Analysis
40. 8.6.5 Strategic Implications (2025–2031)
41. 8.7 Jinan Chenghui-Shuangda Chemical
42. 8.7.1 Company Overview
43. 8.7.2 Key Products & Segments
44. 8.7.3 Financial Performance (2023–2025)
45. 8.7.4 SWOT Analysis
46. 8.7.5 Strategic Implications (2025–2031)
47. 8.8 Wuhan Microsen Technology
48. 8.8.1 Company Overview
49. 8.8.2 Key Products & Segments
50. 8.8.3 Financial Performance (2023–2025)
51. 8.8.4 SWOT Analysis
52. 8.8.5 Strategic Implications (2025–2031)
Competitive Landscape
1. 9.1 Competitive Landscape Overview
2. 9.2 Competitive Intensity Assessment
3. 9.2.1 Competitive Tier Structure
4. 9.2.2 Tier 1: Brand-Led Concentration at the Top
5. 9.2.3 Tier 2: Capability-Rich but Commercially Narrow
6. 9.2.4 Tier 3: Volume Exposure, Limited Transparency
7. 9.2.5 Pricing Environment
8. 9.2.6 Barriers to Entry and Exit
9. 9.3 Key Player Strategies & Positioning
10. 9.4 Competitive Dynamics & Strategic Outlook
11. 9.4.1 Emerging Competitive Threats
12. 9.4.2 Consolidation vs. Fragmentation Outlook
13. 9.4.3 Competitive Response Matrix
14. 9.4.4 Strategic Recommendations for 2025–2031
Porter's Five Forces Analysis
1. 10.1 Threat of New Entrants
2. 10.2 Bargaining Power of Buyers
3. 10.3 Bargaining Power of Suppliers
4. 10.4 Threat of Substitutes
5. 10.5 Competitive Rivalry
PESTLE Analysis
1. 11.1 Political Factors
2. 11.1.1 Healthcare Expenditure Policy and Government Prioritisation of…
3. 11.1.2 Trade Policy and Cross-Border Supply Chain Exposure
4. 11.1.3 Regulatory Nationalism and Domestic Manufacturing Incentives
5. 11.2 Economic Factors
6. 11.2.1 Global Market Valuation and Growth Trajectory
7. 11.2.2 Healthcare Budget Cycles and Institutional Procurement Dynamics
8. 11.2.3 Currency Risk and Pricing Parity
9. 11.2.4 Emerging Market Economic Development and Healthcare Spending G…
10. 11.2.5 Biopharmaceutical Manufacturing Boom as an Incremental Economi…
11. 11.3 Social & Demographic Factors
12. 11.3.1 Ageing Population and Rising Burden of Critical Illness
13. 11.3.2 Growing Prevalence of Chronic Disease and Malnutrition in Clin…
14. 11.3.3 Sports Nutrition and Consumer Wellness
15. 11.3.4 Healthcare Professional Education and Clinical Protocol Standa…
16. 11.4 Technological Factors
17. 11.4.1 Formulation Stability: The Core Technological Advantage
18. 11.4.2 Cell Culture Media Innovation
19. 11.4.3 Fermentation Technology and Synthetic Route Optimisation
20. 11.4.4 Digital Transformation in Hospital Pharmacy and Nutrition Mana…
21. 11.5 Legal & Regulatory Factors
22. 11.5.1 Pharmaceutical-Grade Regulatory Requirements and Market Access…
23. 11.5.2 Customs Classification Ambiguity and Trade Documentation Compl…
24. 11.5.3 Evolving Reimbursement Regulation for Parenteral Nutrition
25. 11.5.4 Pharmacopoeial Standards and Quality Benchmarking
26. 11.5.5 Data Exclusivity and Intellectual Property Considerations
27. 11.6 Environmental Factors
28. 11.6.1 Amino Acid Fermentation: Energy and Resource Intensity
29. 11.6.2 Pharmaceutical Waste and Parenteral Nutrition Packaging
30. 11.6.3 Water Usage and Environmental Discharge Management
31. 11.6.4 Climate Resilience and Agricultural Input Security
32. 11.6.5 Carbon Pricing and Industrial Decarbonisation Policy
33. 11.6.6 PESTLE Summary: Strategic Implications for Market Participants
SWOT Analysis
1. 12.1 Preamble: Scope and Analytical Approach
2. 12.2 Market-Level Strengths
3. 12.2.1 Chemically Superior Stability Relative to Free L-Glutamine
4. 12.2.2 Validated Clinical Evidence Base in Critical Care Nutrition
5. 12.2.3 Institutional Entrenchment Within Leading Parenteral Nutrition…
6. 12.2.4 Independently Verified Cell Culture Application Creating Struc…
7. 12.2.5 Concentrated but Credible Supplier Base with High Technical Ba…
8. 12.3 Market-Level Weaknesses
9. 12.3.1 Absence of Dedicated Customs Classification Codes Limiting Tra…
10. 12.3.2 No Manufacturer-Level Disclosure of Molecule-Specific Revenue
11. 12.3.3 High Price Sensitivity at the Bulk Grade Tier
12. 12.3.4 Narrow Primary Application Creating Revenue Concentration Risk
13. 12.3.5 Limited Consumer-Facing Brand Equity
14. 12.4 Strategic Opportunities
15. 12.4.1 Expanding Critical Care Infrastructure in High-Growth Emerging…
16. 12.4.2 Biopharmaceutical Manufacturing Growth as a Structurally Indep…
17. 12.4.3 Ageing Global Population Driving Structural Uplift in Clinical…
18. 12.4.4 Premiumisation Opportunities in Sports and Functional Nutrition
19. 12.4.5 Formulation Innovation in Ready-to-Use Multi-Chamber Parentera…
20. 12.4.6 Strategic M&A and Vertical Integration Activity
21. 12.5 External Threats
22. 12.5.1 Evolving Clinical Guideline Consensus on Glutamine Supplementa…
23. 12.5.2 Generic Competition and Price Erosion in Pharma-Grade Segments
24. 12.5.3 Currency Volatility and Geopolitical Supply Chain Disruption Risk
25. 12.5.4 Healthcare Budget Constraints Limiting Clinical Nutrition Prot…
26. 12.5.5 Regulatory Complexity Across Jurisdictions Slowing Market Access
27. 12.5.6 Substitution Risk from Alternative Parenteral Nutrition Modali…
28. 12.6 Integrated SWOT Summary Assessment
Future Trends & Outlook
1. 13.1 Formulation Innovation in Parenteral Nutrition Delivery
2. 13.2 Emerging Market Healthcare Infrastructure Development
3. 13.3 Long-Term Market Outlook (2032–2035)
4. 13.4 Investment & M&A Activity Outlook

List of Exhibits

2.1 Exhibit 2.1: Forecast of Global (in USD Mn)
2.2 Exhibit 2.2: Forecast of Global Market YoY Growth Rate & CAGR Summary (in %)
2.3 Exhibit 2.3: Forecast of North America (in USD Mn)
2.4 Exhibit 2.4: Forecast of Europe (in USD Mn)
2.5 Exhibit 2.5: Forecast of Asia Pacific (in USD Mn)
2.6 Exhibit 2.6: Forecast of Latin America (in USD Mn)
2.7 Exhibit 2.7: Forecast of Middle East & Africa (in USD Mn)
2.8 Exhibit 2.8: Forecast of Global (in mt)
2.9 Exhibit 2.9: Forecast of Global Market YoY Growth Rate & CAGR Summary (in %)
2.10 Exhibit 2.10: Forecast of North America (in mt)
2.11 Exhibit 2.11: Forecast of Europe (in mt)
2.12 Exhibit 2.12: Forecast of Asia Pacific (in mt)
2.13 Exhibit 2.13: Forecast of Latin America (in mt)
2.14 Exhibit 2.14: Forecast of Middle East & Africa (in mt)
3.15 Exhibit 3.15: Forecast of 0.99 Purity (Injection-Grade) (in USD Mn)
3.16 Exhibit 3.16: Forecast of 0.99 Purity (Injection-Grade) (in mt)
3.17 Exhibit 3.17: Forecast of 0.985 Purity (Standard Pharmaceutical-Grade) (in USD Mn)
3.18 Exhibit 3.18: Forecast of 0.985 Purity (Standard Pharmaceutical-Grade) (in mt)
3.19 Exhibit 3.19: Forecast of Other/Lower-Purity Grades (in USD Mn)
3.20 Exhibit 3.20: Forecast of Other/Lower-Purity Grades (in mt)
4.21 Exhibit 4.21: Forecast of Pharmaceutical / Clinical & Parenteral Nutrition (in USD Mn)
4.22 Exhibit 4.22: Forecast of Pharmaceutical / Clinical & Parenteral Nutrition (in mt)
4.23 Exhibit 4.23: Forecast of Cell Culture / Biopharmaceutical Manufacturing (in USD Mn)
4.24 Exhibit 4.24: Forecast of Cell Culture / Biopharmaceutical Manufacturing (in mt)
4.25 Exhibit 4.25: Forecast of Food / Sports & Functional Nutrition (in USD Mn)
4.26 Exhibit 4.26: Forecast of Food / Sports & Functional Nutrition (in mt)
4.27 Exhibit 4.27: Forecast of Other (Research, Animal Nutrition) (in USD Mn)
4.28 Exhibit 4.28: Forecast of Other (Research, Animal Nutrition) (in mt)
6.29 Exhibit 6.29: Forecast of North America (in USD Mn)
6.30 Exhibit 6.30: Forecast of USA (in USD Mn)
6.31 Exhibit 6.31: Forecast of Rest of North America (in USD Mn)
6.32 Exhibit 6.32: Forecast of North America (in mt)
6.33 Exhibit 6.33: Forecast of USA (in mt)
6.34 Exhibit 6.34: Forecast of Rest of North America (in mt)
6.35 Exhibit 6.35: Forecast of Europe (in USD Mn)
6.36 Exhibit 6.36: Forecast of Germany (in USD Mn)
6.37 Exhibit 6.37: Forecast of France (in USD Mn)
6.38 Exhibit 6.38: Forecast of Rest of Europe (in USD Mn)
6.39 Exhibit 6.39: Forecast of Europe (in mt)
6.40 Exhibit 6.40: Forecast of Germany (in mt)
6.41 Exhibit 6.41: Forecast of France (in mt)
6.42 Exhibit 6.42: Forecast of Rest of Europe (in mt)
6.43 Exhibit 6.43: Forecast of Asia Pacific (in USD Mn)
6.44 Exhibit 6.44: Forecast of China (in USD Mn)
6.45 Exhibit 6.45: Forecast of Japan (in USD Mn)
6.46 Exhibit 6.46: Forecast of India (in USD Mn)
6.47 Exhibit 6.47: Forecast of Rest of Asia-Pacific (in USD Mn)
6.48 Exhibit 6.48: Forecast of Asia Pacific (in mt)
6.49 Exhibit 6.49: Forecast of China (in mt)
6.50 Exhibit 6.50: Forecast of Japan (in mt)
6.51 Exhibit 6.51: Forecast of India (in mt)
6.52 Exhibit 6.52: Forecast of Rest of Asia-Pacific (in mt)
6.53 Exhibit 6.53: Forecast of Latin America (in USD Mn)
6.54 Exhibit 6.54: Forecast of Rest of Latin America (in USD Mn)
6.55 Exhibit 6.55: Forecast of Latin America (in mt)
6.56 Exhibit 6.56: Forecast of Rest of Latin America (in mt)
6.57 Exhibit 6.57: Forecast of Middle East & Africa (in USD Mn)
6.58 Exhibit 6.58: Forecast of Rest of Middle East & Africa (in USD Mn)
6.59 Exhibit 6.59: Forecast of Middle East & Africa (in mt)
6.60 Exhibit 6.60: Forecast of Rest of Middle East & Africa (in mt)

<p>Fresenius Kabi, Ajinomoto, Kyowa Hakko Bio, Evonik, Jiangsu Chengxin Pharmaceutical, Xi'an Lyphar Biotech Co. Ltd., Jinan Chenghui-Shuangda Chemical, Wuhan Microsen Technology</p>

Single User License (PDF)

This license allows for use of a publication by one person.
This person may print out a single copy of the publication.
This person can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher.
This person cannot share the publication (or any information contained therein) with any other person or persons.
Unless a Enterprise License is purchased, a Single User License must be purchased for every person that wishes to use the publication within the same organization.
Customers who infringe these license terms are liable for a Enterprise license fee.

Site License (PDF)*

This license allows for use of a publication by all users within one corporate location, e.g. a regional office.
These users may print out a single copy of the publication.
These users can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher.
These users cannot share the publication (or any information contained therein) with any other person or persons outside the corporate location for which the publication is purchased.
Unless a Enterprise License is purchased, a Site User License must be purchased for every corporate location by an organization that wishes to use the publication within the same organization.
Customers who infringe these license terms are liable for a Enterprise license fee.

Enterprise License (PDF)*

This license allows for use of a publication by unlimited users within the purchasing organization e.g. all employees of a single company.
Each of these people may use the publication on any computer, and may print out the report, but may not share the publication (or any information contained therein) with any other person or persons outside of the organization.
These employees of purchasing organization can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher.

*If Applicable.